Barriers to Optimal Disease Control for Rheumatoid Arthritis Patients With Moderate and High Disease Activity-Reference-Cited by-同舟云学术

Barriers to Optimal Disease Control for Rheumatoid Arthritis Patients With Moderate and High Disease Activity

Published:2014-01-28 Issue:2 Volume:66 Page:190-196
ISSN:2151-464X
Container-title:Arthritis Care & Research
language:en
Short-container-title:Arthritis Care & Research

Author:

Tymms Kathleen¹,Zochling Jane²,Scott James³,Bird Paul⁴,Burnet Simon⁵,de Jager Julien⁶,Griffiths Hedley⁷,Nicholls Dave⁸,Roberts Lynden⁹,Arnold Mark¹⁰,Littlejohn Geoffrey¹¹

Affiliation:

1. Canberra Rheumatology; Canberra, ACT Australia

2. Menzies Research Institute Tasmania; Hobart, Tasmania Australia

3. Roche Products, Dee Why; New South Wales Australia

4. Combined Rheumatology Practice; Sydney, New South Wales Australia

5. Queen Elizabeth Hospital; Adelaide, South Australia Australia

6. Olser House, Southport; Queensland Australia

7. Barwon Rheumatology Service; Geelong, Victoria Australia

8. Coast Joint Care, Maroochydore; Queensland Australia

9. The Townsville Hospital, Douglas; Queensland Australia

10. Orthopaedic & Arthritis Specialist Centre; Chatswood, New South Wales Australia

11. Monash Medical Centre; Clayton, Victoria Australia

Publisher

Wiley

Subject

Rheumatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/acr.22108/fullpdf

Reference19 articles.

1. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis;Singh;Arthritis Care Res (Hoboken),2012

2. Treating rheumatoid arthritis to target: recommendations of an international task force;Smolen;Ann Rheum Dis,2010

3. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs;Smolen;Ann Rheum Dis,2010

4. Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries;Sokka;Arthritis Rheum,2008

5. Multi-centre, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control;Littlejohn;Arthritis Rheum,2010

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can a simple 0–10 RheuMetric physician estimate of inflammatory activity (DOCINF) depict a detailed swollen joint count (SJC) as accurately as a DAS28 or CDAI in patients with rheumatoid arthritis?;Seminars in Arthritis and Rheumatism;2024-10

2. The NLRP3 Inflammasome as a Pathogenic Player Showing Therapeutic Potential in Rheumatoid Arthritis and Its Comorbidities: A Narrative Review;International Journal of Molecular Sciences;2024-01-03

3. Use of Coordinator Role Improves Access to Rheumatologic Advanced Therapy;The Journal of Rheumatology;2023-11-01

4. Improvement or Worsening of Disease Activity After Switch to Sarilumab in Patients With Rheumatoid Arthritis With a Partial Response to Adalimumab;JCR: Journal of Clinical Rheumatology;2023-03-02

5. Should quantitative assessment of rheumatoid arthritis include measures of joint damage and patient distress, in addition to measures of apparent inflammatory activity?;ACR Open Rheumatology;2022-12-20